Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Steroid Refractory Graft Versus Host Disease
Interventions
- OTHER: Cellular Therapy
- DRUG: Ruxolitinib
Sponsor
M.D. Anderson Cancer Center
Collaborators